Adjuvant trial in melanoma patients comparing rIFN-α to rIFN-γ to Iscador to a control group after curative resection of high risk primary (≥3 MM) or regional lymphnode metastasis (EORTC 18871)U.R. Kleeberg, Stefan Suciu, F. Lejeune et al.|European Journal of Cancer|1999Cited by 61